Effects of Stable Strontium Supplementation

Skoryna, Stanley C.; Fuskova, M.

doi:10.1007/978-1-4684-3698-3_35

Cited by 7 publications

(7 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevention of bone loss induced by S12911, an acid compound containing two atoms of strontium per molecule, was associated with a dose‐dependent increase in plasma, urine, and bone strontium concentrations. Comparable dose‐dependent changes were previously reported in rats, mice, and humans treated with natural monovalent strontium salts (16–18,28) . The marked increase in plasma strontium induced by S12911 treatment had no effect on plasma calcium and magnesium.…”

Section: Discussionsupporting

confidence: 64%

An Uncoupling Agent Containing Strontium Prevents Bone Loss by Depressing Bone Resorption and Maintaining Bone Formation in Estrogen-Deficient Rats

Marie

Hott

Modrowski

et al. 2005

Journal of Bone and Mineral Research

122

View full text Add to dashboard Cite

Trabecular bone loss in estrogen deficiency is associated with enhanced bone resorption with a smaller increase in bone formation. We previously reported that low doses of strontium can increase trabecular bone volume in rodents by affecting bone resorption and formation. In this study we determined the effect of a new divalent strontium salt (S12911) on bone loss induced by E2 deficiency. Sprague-Dawley female rats (230 g, n = 15-25 per group) were sham operated or ovariectomized (OVX) and treated with 170-estradiol (E2, 10 pg/kg/day, sc) or S12911 by gavage at the dose of 77, 154, or 308 mg/kg/day or the vehicle. Treatment for 60 days with S12911 resulted in a dose-dependent increase in plasma, urine, and bone strontium concentrations without any deleterious effect on total or skeletal growth. OVX rats were osteopenic compared to sham rats as shown by decreased femoral dry bone weight and mineral content measured on bone ash and by DXA. Treatment of OVX rats with S12911 prevented bone loss as bone ash and bone mineral content were restored to the values in sham rats. Trabecular bone volume measured by histomorphometry on the tibia1 metaphysis was decreased by 46% in OVX rats and was corrected by E2. Treatment of OVX rats with S12911 increased the trabecular bone volume by 30-36%. Histomorphometric indices of bone resorption (osteoclast surface and number) were increased in OVX rats and were reduced by S12911 to the levels in sham rats. In contrast to this inhibitory effect on bone resorption, the osteoid surface, osteoblast surface, mineral apposition rate, and bone formation rate were as high in OVX rats treated with S12911 as in untreated OVX rats. In addition, plasma osteocalcin (OC) and alkaline phosphatase (ALP) levels remained elevated or were further increased in OVX rats treated with S12911. In contrast, treatment with E2 reduced both bone resorption and formation and plasma ALP and OC to the levels in sham rats. The data indicate that the divalent strontium salt S12911 is acting as an uncoupling agent that can prevent the femoral osteopenia and partially prevent the trabecular bone loss in E2-deficient rats by inhibiting bone resorption without reducing bone formation.

show abstract

Section: Discussionsupporting

confidence: 64%

An Uncoupling Agent Containing Strontium Prevents Bone Loss by Depressing Bone Resorption and Maintaining Bone Formation in Estrogen-Deficient Rats

Marie

Hott

Modrowski

et al. 2005

Journal of Bone and Mineral Research

122

View full text Add to dashboard Cite

show abstract

“…McCaslin and Janes (11) reported that marked subjective improvement was experienced by 80% of patients with osteoporosis who had been treated with strontium. In addition, serum strontium concentrations of approximately 60 pM decreased bone pain and in creased mineralization, as observed radiographically, in patients with metastatic bone cancer (10). Furthermore, a similar beneficial effect of strontium on bone resorption was also found in our previous in vitro study (5).…”

Section: Discussionsupporting

confidence: 80%

“…In addition to these toxic effects of strontium, clinical beneficial effects have been reported by Skoryna and Fuskova in that low doses of strontium remineralize skeletal lesions and increase bone mass in patients with metastatic bone cancer. These authors have drawn a distinction between pharmacological and toxic levels in strontium therapy (10). In addition, it has also been reported that patients with osteoporosis show a favorable response to treatment with strontium (11).…”

Section: Administrationmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Strontium on Calcium Metabolism in Rats II. Strontium Prevents the Increased Rate of Bone Turnover in Ovariectomized Rats

Morohashi

Sano

Yamada

1995

Japanese Journal of Pharmacology

View full text Add to dashboard Cite

ABSTRACT-Strontium at low doses has been used to treat osteoporosis. However, excessive doses can disturb calcium metabolism. The aim of the present study was to determine a dose that does not have any significant toxic effects on calcium contents in bone and calcium metabolism, and, consequently, to distinguish between pharmacological and toxic doses in rats. The rats were divided into a control, 0.05% Sr, 0.10%-Sr and 0.50%-Sr groups (strontium intake approx. 0, 87.5, 175 and 875 pcmol/day, respectively). All of the rats were pair-fed their respective diets containing various doses of strontium in single metabolic cages from when they were 36 to 63 days old. When the rats were 60 days old, bone formation, bone resorp tion, calcium balance and intestinal calcium absorption were calculated as calcium metabolic parameters over a 3-day period using calcium balance and kinetic studies. At the age of 64 days, the rats were sacrificed under anesthesia, and the femur and blood were collected. Calcium and strontium levels in the bone and serum were then measured. In the strontium groups that received less than 175 pmol/day, none of the calcium metabolic parameters were significantly affected. However, the calcium contents in the bone were significantly increased in the group that received 87.5 pmol/day group. On the other hand, in the group that received the highest dose of strontium (875 pmol/day), all of the calcium metabolic parameters measured were markedly suppressed. A decrease in calcium level in both the bone and serum was also observed. These results suggest that strontium at doses of less than 175 , imol per day does not have a toxic effect on calcium contents in bone or calcium metabolism in rats, and a dose of 87.5 pmol/day may be adopted for future evaluations of the efficacy of strontium in various experimental skeletal diseases.

show abstract

“…Oral administration of excess Sr in rats inhibited the increase in Ca intestinal absorption normally stimulated by vitamin D (154) . The carbonate, gluconate and chloride salts of Sr have also been reported to inhibit vitamin D activity in rats (136) , leading to bone malformation, while Sr ions have been reported to produce rickets in rats by inhibiting the renal production of vitamin D (155) .…”

Section: Risks Nutritional Interactions and Consequences On Bone Hementioning

confidence: 99%

Minerals and vitamins in bone health: the potential value of dietary enhancement

Bonjour¹,

et al. 2009

View full text Add to dashboard Cite

Nutrition is important to bone health, and a number of minerals and vitamins have been identified as playing a potential role in the prevention of bone diseases, particularly osteoporosis. Despite this, there is currently no consensus on maximum levels to allow in food or as dietary supplements. The benefits of supplementation of populations at risk of osteoporosis with Ca and vitamin D are well established. Prolonged supplementation of Ca and vitamin D in elderly has been shown to prevent bone loss, and in some intervention studies to prevent fragility fractures. Although P is essential to bone health, the average intake is considered to be more than sufficient and supplementation could raise intake to adverse levels. The role of vitamin K in bone health is less well defined, though it may enhance the actions of Ca and vitamin D. Sr administered in pharmacological doses as the ranelate salt was shown to prevent fragility fractures in postmenopausal osteoporosis. However, there is no hard evidence that supplementation with Sr salts would be beneficial in the general population. Mg is a nutrient implicated in bone quality, but the benefit of supplementation via foodstuffs remains to be established. A consensus on dietary supplementation for bone health should balance the risks, for example, exposure of vulnerable populations to values close to maximal tolerated doses, against evidence for benefits from randomised clinical trials, such as those for Ca and vitamin D. Feedback from community studies should direct further investigations and help formulate a consensus on dietary supplementation for bone health.

show abstract

Effects of Stable Strontium Supplementation

Cited by 7 publications

References 59 publications

An Uncoupling Agent Containing Strontium Prevents Bone Loss by Depressing Bone Resorption and Maintaining Bone Formation in Estrogen-Deficient Rats

An Uncoupling Agent Containing Strontium Prevents Bone Loss by Depressing Bone Resorption and Maintaining Bone Formation in Estrogen-Deficient Rats

Effects of Strontium on Calcium Metabolism in Rats II. Strontium Prevents the Increased Rate of Bone Turnover in Ovariectomized Rats

Minerals and vitamins in bone health: the potential value of dietary enhancement

Contact Info

Product

Resources

About